Skip to main content
Premium Trial:

Request an Annual Quote

ChromaCode Raises $12M in Series B Round

NEW YORK (GenomeWeb) – Molecular diagnostics firm ChromaCode said today it has raised $12 million in a Series B funding round.

The round was led by New Enterprise Associates with participation from existing investors, Domain Associates and Okapi Ventures.

The new funds will be used to further develop and establishing a commercial infrastructure for the firm's High-Definition Polymerase Chain Reaction (HDPCR) method, a software and assay technology that uses existing real-time PCR instruments and digital signal processing to improve molecular analyses. The HDPCR method relies on patented mathematical methods and algorithmic enhancements to enrich signal processing from life science instrumentation, the firm noted in a statement, enabling multiplexing on existing qPCR instruments.

ChromaCode also announced today that it has appointed Alex Dickinson, a former senior vice president of strategic initiatives responsible for Illumina's cloud genomics and PCR initiatives, as its executive chairman.

"Next-generation sequencing-based research has delivered a vast array of genetic markers for a multitude of diseases," Dickinson said in a statement. "However, the high cost, complexity, and scarcity of NGS has limited the clinical impact of this work. ChromaCode's HDPCR enables multiplexed tests on the qPCR instruments that are used every day in all the world's molecular diagnostic labs, enabling universal access to leading-edge diagnostics."

Filed under

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.